Drug Trial Radar · NCT07412470
A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation
Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
526
Planned (sponsor's estimate)
Start
Mar 13, 2026
Primary completion
Aug 15, 2029
Study completion Aug 15, 2033
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Feb 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this open-label, randomized, active-comparator-controlled study is to determine the efficacy and safety of frexalimab subcutaneous administrations up to 5 years compared to tacrolimus capsules in adults undergoing kidney transplantation. Participants aged 18 to 70 years who have low-to-moderate immunologic risk of graft rejection and receive their first kidney transplant are eligible if they meet all inclusion and no exclusion criteria. Study details include: * The study and treatment duration will be up to approximately 5 years. * The number of visits will be approximately 38.
Conditions
- Kidney Transplant Rejection
Interventions
FrexalimabDrug
Pharmaceutical form:Solution for injection-Route of administration:IV
FrexalimabDrug
Pharmaceutical form:Solution for injection-Route of administration:SC
TacrolimusDrug
Pharmaceutical form:Capsule-Route of administration:Oral
rabbit anti-thymocyte globulinDrug
Pharmaceutical form:Solution for injection-Route of administration:IV
mycophenolate mofetilDrug
Pharmaceutical form:Tablet or capsule-Route of administration:Oral
mycophenolate sodiumDrug
Pharmaceutical form:Tablet-Route of administration:Oral
methylprednisoloneDrug
Pharmaceutical form:Solution for injection-Route of administration:IV
prednisoneDrug
Pharmaceutical form:Tablet-Route of administration:Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Composite efficacy failure rate (BPAR, graft loss, and death) by 1 year post kidney transplantationTime frame: by 1 year
Locations
73 sites in 18 countries. Site status is shown where the registry gives one.
University of California San Francisco - Parnassus Heights- Site Number : 8400001
San Francisco, California · Recruiting
Emory University Hospital- Site Number : 8400002
Atlanta, Georgia · Recruiting
Edward Hines, Jr. Veterans Affairs Hospital- Site Number : 8400010
Hines, Illinois · Recruiting
University of Kansas Medical Center- Site Number : 8400044
Kansas City, Kansas · Recruiting
University of Maryland School of Medicine - Baltimore- Site Number : 8400045
Baltimore, Maryland · Recruiting
Brigham & Women's Hospital- Site Number : 8400049
Boston, Massachusetts · Recruiting
University of Michigan Health System - Ann Arbor- Site Number : 8400022
Ann Arbor, Michigan · Recruiting
The Mount Sinai Hospital- Site Number : 8400027
New York, New York · Recruiting
Columbia University Irving Medical Center- Site Number : 8400007
New York, New York · Recruiting
Weill Cornell Medical College- Site Number : 8400005
New York, New York · Recruiting
Montefiore Medical Center - Moses Campus- Site Number : 8400006
The Bronx, New York · Recruiting
The Ohio State University- Site Number : 8400025
Columbus, Ohio · Recruiting
VCU Massey Cancer Center: Dalton Oncology Clinic- Site Number : 8400004
Richmond, Virginia · Recruiting
University of Washington Medical Center- Site Number : 8400035
Seattle, Washington · Recruiting
Investigational Site Number : 0320002
Buenos Aires, Argentina · Recruiting
Investigational Site Number : 0320001
Corrientes, Argentina · Recruiting
Investigational Site Number : 0360003
Sydney, New South Wales, Australia · Recruiting
Investigational Site Number : 0360002
Adelaide, South Australia, Australia · Recruiting
Investigational Site Number : 0360004
Clayton, Victoria, Australia · Recruiting
Investigational Site Number : 0360001
Parkville, Victoria, Australia · Recruiting
Investigational Site Number : 0560002
Brussels, Belgium · Recruiting
Investigational Site Number : 0560001
Leuven, Belgium · Recruiting
Hospital do Rim e Hipertensão- Site Number : 0760001
São Paulo, Brazil · Recruiting
Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo- Site Number : 0760006
São Paulo, Brazil · Recruiting
Hospital Geral de Fortaleza - HGF- Site Number : 0760007
Fortaleza, Ceará, Brazil · Recruiting
Irmandade da Santa Casa de Misericórdia de Porto Alegre- Site Number : 0760004
Porto Alegre, Rio Grande do Sul, Brazil · Recruiting
Investigational Site Number : 1520005
Santiago, Reg Metropolitana de Santiago, Chile · Recruiting
Investigational Site Number : 1520004
Santiago, Reg Metropolitana de Santiago, Chile · Recruiting
Investigational Site Number : 1560018
Beijing, China · Recruiting
Investigational Site Number : 1560003
Chengdu, China · Recruiting
Investigational Site Number : 1560007
Guangzhou, China · Recruiting
Investigational Site Number : 1560020
Guangzhou, China · Recruiting
Investigational Site Number : 1560002
Hangzhou, China · Recruiting
Investigational Site Number : 1560012
Jinan, China · Recruiting
Investigational Site Number : 1560017
Nanchang, China · Recruiting
Investigational Site Number : 1560008
Nanning, China · Recruiting
Investigational Site Number : 1560016
Shanghai, China · Recruiting
Investigational Site Number : 1560001
Shanghai, China · Recruiting
Investigational Site Number : 1560011
Tianjin, China · Recruiting
Investigational Site Number : 1560006
Wuhan, China · Recruiting
Showing 40 of 73 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.